A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Trial Details

NCT ID

NCT06962865

Phase

PHASE2

Sponsor

RemeGen Co., Ltd.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• RC108
• Furmonertinib Mesilate Tablets Monotherapy

Locations (sample)

• Beijing, China|39.9075,116.39723
• Beijing, China|39.9075,116.39723
• Binzhou, China|37.36667,118.01667
• Changchun, China|43.88,125.32278
• Changsha, China|28.19874,112.97087

Key Eligibility Criteria

• Voluntarily participate in the study and signed the ICF;
• Male or female, aged 18-75 years;
• All participants to be enrolled must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced (stage IIIB/II…
• For previously locally advanced or recurrent metastatic disease not treated with systemic antitumor therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.